The Swiss Clinical Trial Organisation (SCTO) is a research infrastructure committed to promoting high-quality, patient-oriented clinical research in Switzerland. The SCTO is an independent, non-profit organisation funded by the State Secretariat for Education, Research and Innovation (SERI) and the Swiss National Science Foundation (SNSF), and it has been mandated to advance academic clinical research in Switzerland by serving as a nationwide collaboration platform and international networking partner.

The SERI commissioned an independent evaluation of the SCTO’s Clinical Trial Unit (CTU) Network and platforms for the time period of 2017–2020. The evaluation focused on the following three key areas:

1. the significance of the CTUs’ services for clinical researchers
2. the role of the CTU Network with regard to challenges in clinical research
3. an evaluation of the SCTO Platforms’ role.

The recently released evaluation report (available in German) summarises the results of the evaluation, presents initial conclusions, and identifies action points.

Overall, a large majority of respondents were satisfied with both the services provided by the various local CTUs and their professional expertise; most respondents rated cooperation with the CTUs as efficient. In terms of barriers for using the CTUs, respondents often mentioned costs as a limiting factor.

All respondents credited the SCTO umbrella organisation with serving a supportive role for collaboration and communication within the CTU Network. In addition, the SCTO’s external role as a point of contact for third parties received a positive rating. All respondents rated the role of the SCTO Platforms very positively and agreed with the platforms’ topic-based focus. Products created by the platforms were viewed as having high quality, and the platforms’ work was perceived as being both effective and efficient.

The SCTO’s Steering Board is pleased about the overall positive result of the evaluation. The Board will carefully analyse the action points identified in order to start putting appropriate measures in place that will improve and further develop the organisation.

Show more

Hide

We are very pleased to announce that Victoria Sarraf-Mikaelian will assume the role of Managing Director of the SCTO as of 1 January 2023. She will succeed Annette Magnin, who is leaving the SCTO at the end of November 2022.

Victoria has many years of professional experience in the public and private sectors. As a pharmacist with a master’s in business administration, she holds both a scientific and an economic degree. Currently, she is Head of Analysis & Strategies in Biomedicine at the Swiss Federal Office of Public Health (FOPH).

Victoria will add value to the SCTO with her knowledge of political issues and processes in the field of health, of the federal government's strategy for supporting research, innovation, and industry, and of networks and umbrella organisations in the biomedical field. Moreover, she is experienced in managing and coordinating cross-functional teams and projects and has wide-ranging expertise in the entire pharmaceutical research and development chain.

Victoria’s excellent background equips her well to support the SCTO with upcoming challenges and help it further develop as an organisation. We are very much looking forward to working with Victoria!

Show more

Hide

Our remuneration policy provides guidance on the remuneration of patients or representatives of the public when they are involved in clinical research projects within our network. The policy also describes the conditions for reimbursing accommodation and travel expenses incurred.

This policy can also be used outside of our network as a model for PPI remuneration. It is available in four languages on our website:
English: SCTO Remuneration Policy for Patient and Public Involvement (PPI) Activities
Deutsch: Patienten- und Öffentlichkeitsbeteiligung: Vergütungsrichtlinie der SCTO
Français: Activités d’implication des patient•e•s et du public: directives de rémunération de la SCTO
Italiano: Coinvolgimento di pazienti e pubblico: direttiva sulla remunerazione della SCTO

Show more

Hide

How can the use of artificial intelligence (AI) and machine learning (ML) benefit clinical research? What are the challenges and risks of these new approaches? We invited leading international experts to come to Lugano on 15 June to shed some light on these current issues. In addition, key Swiss stakeholders in clinical research discussed how they address these new technological advances and how they are preparing for the future.

Attended by over 150 people, this year’s SCTO Symposium was organised in close cooperation with Ente Ospedaliero Cantonale (EOC). You can find a selection of the videos and PDFs of the presentations on the SCTO Symposium 2022 section of our website.

Show more

Hide

The Swiss Personalized Health Network (SPHN) has launched a call for Demonstrator projects. These projects aim to demonstrate the added value of SPHN data resources and infrastructure elements for data-driven personalized health research, clinical and public health research, and clinical use. Submission deadline for applications is 31 August 2022.

The application also includes a lay summary that explains the project proposal to the public and describes how the Demonstrator project will be of benefit to patients.

For more information, please visit https://sphn.ch.
You can find useful information on the topic of patient and public involvement in academic clinical research in our dedicated section on this website.

Show more

Hide

On 13 April, the Federal Council submitted a dispatch report to Parliament on Switzerland's access to six European research infrastructure networks. Joining these networks would enable Swiss researchers to participate in them actively and on an equal footing.

In order to simplify the process for Switzerland to join these networks in the future, the Federal Council has also proposed an amendment to the Federal Act on the Promotion of Research and Innovation (RIPA). This would give the Federal Council powers to make the decision on joining European Research Infrastructure Consortium (ERIC) research infrastructures, as is the case with other international research infrastructures with different legal forms.

Federal Council’s press release
Provisional message on Switzerland joining ERIC research infrastructures (available in French, German, and Italian)

Show more

Hide

The Swiss National Science Foundation (SNSF) has opened its eighth call for its Investigator Initiated Clinical Trials (IICT) programme. This programme supports clinical trials on underresearched topics that meet medical as well as social needs. In both their letter of intent (LOI) and their application, grant applicants must address how they actively involve or plan to involve patients and the public (PPI) in their research projects.

For researchers who are interested in applying to the IICT 2022 programme, the SCTO is offering an online course twice entitled PPI in a Nutshell on 12 April and 6 May. In this course, we will discuss why PPI is particularly useful when planning and developing clinical trials. We will also provide practical tips and examples for an effective and meaningful approach to PPI. This online course is free of charge and will be held in English.

• Programme and registration for the online course PPI in a Nutshell
• More information on the SNSF’s current Investigator Initiated Clinical Trials (IICT) call 

Show more

Hide

During the SCTO’s annual forum on 26 January 2022, we discussed the new EU requirements, their relevance for Switzerland, and what needs to be considered from an academic perspective when submitting applications for clinical trials in Europe.

In addition, the European Medicines Agency (EMA) – one of the founding members of the ICH – provided participants with an overview of the vision and objectives of the ongoing, comprehensive renovation of the ICH Good Clinical Practice (GCP) Guideline. During the ensuing discussion session, we considered how this renovation could affect our daily work in clinical research.

You can download videos of the presentations made at the SCTO’s digital forum on 26 January 2022 and related PDFs.

• Watch videos of the presentations on Vimeo: SCTO Forum 2022: EU CTIS launch and ICH GCP renovation – how will they affect Switzerland?
• Download the event’s programme and PDFs from the presentations in our Events section: Forum 2022. 

Show more

Hide

On 13 February, Swiss voters will decide whether research on animals and humans should be forbidden in Switzerland. Both the academic clinical research community and patient organisations are advocating for a clear no vote on this radical initiative. In our newsletter of 3 February 2022 we have collected the most important happenings from the past few weeks that are connected to this topic as well as related reading and listening recommendations.

SCTO newsletter of 3 February 2022

Show more

Hide

In their seventh call, Personalized Health and Related Technologies (PHRT) invites applicants to collaborate with hospitals and clinics and submit project proposals for:

1. Interdisciplinary doctoral, so-called iDoc Projects, 
2. Interdisciplinary Postdoc, so-called iPostdoc Projects, 
3. Technology Translation Projects (TT Projects),
4. PH/PM Research Projects, and
5. Imaging Projects being part of the PHRT Imaging Hub.

The submission deadline for all proposal types is 17 April 2022.

For more information about the call and about Personalized Health and Related Technologies, visit the PHRT’s website.

Show more

Hide

We cannot direct the wind, but we can adjust the sails.
Aristotle

The SCTO and its Clinical Trial Unit Network are supported by the federal government as a research infrastructure of national importance. We base our strategic course on two mandates: our service level agreements with the State Secretariat for Education, Research and Innovation and with the Swiss National Science Foundation. These agreements outline our main areas of activity for the upcoming four years, which we and our Steering Board use as a basis for setting our priorities for the current funding period and for defining our objectives.

Join us on our journey and learn more about where we are headed in the current funding period:

• Vision and mission
• Strategic priorities 2021–2024
   
• Our organisation
• Our team

Show more

Hide